3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
NETWORK
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Lymphoma
45
Breast Neoplasms
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
42
Lymphoma, Large B-Cell, Diffuse
41
Lymphoma, Non-Hodgkin
39
Multiple Myeloma
35
Leukemia
34
Leukemia, Lymphocytic, Chronic, B-Cell
32
Melanoma
31
Recurrence
29
Leukemia, Myeloid, Acute
28
Lymphoma, Follicular
27
Lymphoma, B-Cell
25
Ovarian Neoplasms
23
Lymphoma, Mantle-Cell
23
Neoplasm Metastasis
21
Hematologic Neoplasms
19
Myelodysplastic Syndromes
18
Hodgkin Disease
18
Pancreatic Neoplasms
17
Burkitt Lymphoma
16
Neoplasms
13
Carcinoma, Non-Small-Cell Lung
13
Triple Negative Breast Neoplasms
12
Lymphoma, B-Cell, Marginal Zone
12
Colorectal Neoplasms
12
Stomach Neoplasms
11
Waldenstrom Macroglobulinemia
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Carcinoma, Hepatocellular
9
Interventions
carfilzomib
2
Dexamethasone
2
Cyclophosphamide
2
tivozanib
1
tislelizumab
1
pembrolizumab
1
neratinib
1
Nivolumab
1
Interleukin-15
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cisplatin
1
Capecitabine
1
Calcium Dobesilate
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Disease
×
Cyclophosphamide
×
Clear all
NCT01857115
2024-11-13
wCCyd
European Myeloma Network B.V.
Phase 1/2
Completed
63 enrolled
NCT02204241
2023-07-03
CCD
European Myeloma Network B.V.
Phase 1/2
Completed
36 enrolled